ArriVent BioPharma (AVBP) News Today → Millionaire investor and Republican donor makes surprising election prediction (From InvestorPlace) (Ad) Free AVBP Stock Alerts $17.93 +0.23 (+1.30%) (As of 04:27 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 3:26 AM | americanbankingnews.comArriVent BioPharma, Inc. to Post Q2 2024 Earnings of ($0.75) Per Share, Lifesci Capital Forecasts (NASDAQ:AVBP)May 12 at 5:47 AM | americanbankingnews.comArriVent BioPharma (NASDAQ:AVBP) Earns Buy Rating from HC WainwrightMay 10 at 12:06 AM | markets.businessinsider.comBuy Rating for ArriVent BioPharma Amid Strong Financials and Promising Clinical TrialsMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for ArriVent BioPharma on Strong Firmonernib Prospects and Financial StabilityMay 9, 2024 | marketbeat.comArriVent BioPharma's (AVBP) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $25.00 target price on shares of ArriVent BioPharma in a research note on Thursday.May 8, 2024 | investorplace.comAVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024May 8, 2024 | globenewswire.comArriVent BioPharma Reports First Quarter 2024 Financial ResultsMay 3, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for ArriVent BioPharma, Inc.'s Q1 2024 Earnings (NASDAQ:AVBP)May 2, 2024 | marketbeat.comArriVent BioPharma, Inc. to Post Q1 2024 Earnings of ($1.25) Per Share, HC Wainwright Forecasts (NASDAQ:AVBP)ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Analysts at HC Wainwright issued their Q1 2024 earnings estimates for ArriVent BioPharma in a research report issued on Tuesday, April 30th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($1.25) for tMay 1, 2024 | nasdaq.comHC Wainwright & Co. Initiates Coverage of ArriVent BioPharma (AVBP) with Buy RecommendationApril 30, 2024 | marketbeat.comHC Wainwright Begins Coverage on ArriVent BioPharma (NASDAQ:AVBP)HC Wainwright initiated coverage on shares of ArriVent BioPharma in a research report on Tuesday. They set a "buy" rating and a $25.00 price target for the company.April 26, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Trading Up 6%ArriVent BioPharma (NASDAQ:AVBP) Trading Up 6%April 25, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Sets New 1-Year Low at $14.35ArriVent BioPharma (NASDAQ:AVBP) Hits New 12-Month Low at $14.35April 22, 2024 | globenewswire.comArriVent Appoints Kristine Peterson to its Board of DirectorsApril 18, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Sets New 1-Year Low at $15.38ArriVent BioPharma (NASDAQ:AVBP) Hits New 1-Year Low at $15.38April 17, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Down 3.3% ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 3.3%April 12, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Sets New 52-Week Low at $16.83ArriVent BioPharma (NASDAQ:AVBP) Reaches New 12-Month Low at $16.83April 11, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Stock Price Up 3.1%ArriVent BioPharma (NASDAQ:AVBP) Trading 3.1% HigherApril 8, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Trading Down 2.4%ArriVent BioPharma (NASDAQ:AVBP) Shares Down 2.4%April 3, 2024 | marketbeat.comLifesci Capital Comments on ArriVent BioPharma, Inc.'s FY2024 Earnings (NASDAQ:AVBP)ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Research analysts at Lifesci Capital lifted their FY2024 earnings per share (EPS) estimates for ArriVent BioPharma in a report released on Monday, April 1st. Lifesci Capital analyst S. Slutsky now forecasts that the company will earn ($4.53)April 1, 2024 | markets.businessinsider.comBuy Rating on ArriVent BioPharma Highlighting Furmonertinib’s Potential in NSCLC Treatment LandscapeApril 1, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading VolumeArriVent BioPharma (NASDAQ:AVBP) Sees Unusually-High Trading VolumeMarch 29, 2024 | finanznachrichten.deArriVent BioPharma, Inc.: ArriVent BioPharma Reports Full Year 2023 Financial ResultsMarch 28, 2024 | businesswire.comInnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor FurmonertinibMarch 28, 2024 | msn.comArriVent BioPharma reports FY resultsMarch 28, 2024 | globenewswire.comArriVent BioPharma Reports Full Year 2023 Financial ResultsMarch 26, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Stock Price Up 5.2%ArriVent BioPharma (NASDAQ:AVBP) Trading Up 5.2%March 25, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Down 2.8% ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 2.8%March 21, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Sets New 12-Month Low at $17.63ArriVent BioPharma (NASDAQ:AVBP) Sets New 12-Month Low at $17.63March 20, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down to $18.13ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down to $18.13March 18, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Trading Down 5.6%ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 5.6%March 14, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Hits New 12-Month Low at $18.06ArriVent BioPharma (NASDAQ:AVBP) Sets New 1-Year Low at $18.06March 6, 2024 | uk.investing.comArrivent Biopharma Inc (AVBP)March 5, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down to $22.75ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down to $22.75March 5, 2024 | markets.businessinsider.comBuy Rating on ArriVent BioPharma: Advancing NSCLC Treatment with Promising Furmonertinib ProspectsFebruary 28, 2024 | marketbeat.comArriVent BioPharma, Inc.'s (NASDAQ:AVBP) Quiet Period Will End on March 6thArriVent BioPharma's (NASDAQ:AVBP - Get Free Report) quiet period will expire on Wednesday, March 6th. ArriVent BioPharma had issued 9,722,222 shares in its initial public offering on January 26th. The total size of the offering was $174,999,996 based on an initial share price of $18.00. During ArriVent BioPharma's quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.February 20, 2024 | marketbeat.comJefferies Financial Group Initiates Coverage on ArriVent BioPharma (NASDAQ:AVBP)Jefferies Financial Group started coverage on shares of ArriVent BioPharma in a research note on Tuesday. They set a "buy" rating and a $35.00 target price for the company.February 9, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 3.6%ArriVent BioPharma (NASDAQ:AVBP) Shares Down 3.6% Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk’s Next Move Will Disrupt AI Forever (Ad)A revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100. Get all the information here. AVBP Media Mentions By Week AVBP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVBP News Sentiment▼1.160.58▲Average Medical News Sentiment AVBP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVBP Articles This Week▼123▲AVBP Articles Average Week Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aerovate Therapeutics News Today Calliditas Therapeutics AB (publ) News Today Y-mAbs Therapeutics News Today IGM Biosciences News Today Phathom Pharmaceuticals News Today GH Research News Today Stoke Therapeutics News Today Pharming Group News Today ORIC Pharmaceuticals News Today Astria Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVBP) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsObama’s Forever Term [exposed]Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
